LH

+ Watchlist + Portfolio

Labcorp Holdings Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $330.44
52-Week Range: $244.52 – $338.19
Market Cap: $26.99B
P/E (TTM): 27.53
EPS (TTM): 12.09
Dividend Yield: 0.87%

Advanced Metrics

Price/Book: 3.13
PEG Ratio: 1.38
Return on Equity: 11.73%
Return on Assets: 5.53%
Gross Margin: 28.88%
Operating Margin: 12.24%
Profit Margin: 6.99%
Current Ratio: 1.80
Debt/Equity: 0.79
Total Debt: $6.82B
Free Cash Flow: $892.05M
Revenue Growth: 5.80%
Earnings Growth: 28.20%
Enterprise Value: $33.50B

LH Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$11.86B	$12.16B	$13.01B	$13.95B
Cost of Revenue	$8.15B	$8.80B	$9.38B	$9.94B
Gross Profit	$3.71B	$3.36B	$3.62B	$4.01B
Selling, General & Admin	$1.76B	$2.02B	$2.23B	$2.22B
Operating Expenses	$1.96B	$2.24B	$2.49B	$2.50B
Operating Income	$1.75B	$1.12B	$1.14B	$1.52B
EBITDA	$1.95B	$1.35B	$1.81B	$2.01B
Pretax Income	$1.24B	$568.90M	$959.50M	$1.11B
Income Tax	$233.90M	$188.50M	$212.40M	$229.80M
Net Income	$1.28B	$418.00M	$746.00M	$876.50M
Diluted EPS	13.97	4.77	8.84	10.46
Diluted Shares	91.60M	87.60M	84.40M	83.80M

LH Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$320.60M	$536.80M	$1.52B	$532.30M
Receivables	$2.00B	$2.10B	$2.10B	$2.26B
Inventory	$470.60M	$474.60M	$493.20M	$534.70M
Current Assets	$4.63B	$3.77B	$4.81B	$4.02B
Total Assets	$20.16B	$16.73B	$18.38B	$18.39B
Current Liabilities	$3.08B	$3.23B	$3.33B	$2.82B
Long-Term Debt	$5.04B	$4.05B	$5.33B	$5.08B
Total Debt	$6.25B	$5.95B	$7.27B	$6.53B
Total Liabilities	$10.04B	$8.83B	$10.31B	$9.76B
Retained Earnings	$10.58B	$7.89B	$8.30B	$8.64B
Shareholders' Equity	$10.10B	$7.88B	$8.05B	$8.62B
Working Capital	$1.55B	$540.20M	$1.48B	$1.20B
Net Debt	$5.02B	$4.52B	$4.81B	$5.05B

LH Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$1.96B	$1.33B	$1.59B	$1.64B
Capital Expenditure	-$429.30M	-$453.60M	-$489.90M	-$434.50M
Free Cash Flow	$1.53B	$874.10M	$1.10B	$1.21B
Depreciation & Amortisation	$537.20M	$577.30M	$643.50M	$681.10M
Stock-Based Compensation	$116.80M	$128.70M	$116.70M	$125.80M
Investing Cash Flow	-$1.65B	-$1.17B	-$1.37B	-$1.19B
Financing Cash Flow	-$1.32B	-$59.30M	$779.90M	-$1.46B
Dividends Paid	-$195.20M	-$254.00M	-$243.10M	-$240.70M
Share Repurchases	-$1.10B	-$1.00B	-$250.10M	-$450.00M
Net Change in Cash	-$1.13B	$96.90M	$998.90M	-$1.01B

LH Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$3.35B	$3.53B	$3.56B	$3.52B	$3.54B
Cost of Revenue	$2.40B	$2.48B	$2.54B	$2.52B	$2.52B
Gross Profit	$948.00M	$1.05B	$1.03B	$993.20M	$1.01B
Selling, General & Admin	$546.00M	$579.30M	$552.40M	$538.60M	$551.00M
Operating Expenses	$615.60M	$647.60M	$621.90M	$611.20M	$626.60M
Operating Income	$332.40M	$398.60M	$403.20M	$382.00M	$387.20M
EBITDA	$498.00M	$532.10M	$564.00M	$418.60M	$548.10M
Pretax Income	$275.20M	$304.70M	$337.00M	$190.60M	$319.70M
Income Tax	$62.20M	$66.40M	$75.50M	$25.70M	$41.70M
Net Income	$212.80M	$237.90M	$261.10M	$164.70M	$277.80M
Diluted EPS	2.52	2.84	3.12	1.98	3.35
Diluted Shares	84.30M	83.90M	83.70M	83.20M	82.90M

LH Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$369.40M	$647.30M	$598.10M	$532.30M	$981.10M
Receivables	$2.27B	$2.28B	$2.27B	$2.26B	$2.45B
Inventory	$488.30M	$508.10M	$521.50M	$534.70M	$497.70M
Current Assets	$3.79B	$4.09B	$4.08B	$4.02B	$4.56B
Total Assets	$17.60B	$18.06B	$18.26B	$18.39B	$19.09B
Current Liabilities	$2.06B	$2.72B	$2.63B	$2.82B	$2.64B
Long-Term Debt	$5.57B	$5.08B	$5.08B	$5.08B	$5.83B
Total Debt	$6.52B	$6.55B	$6.53B	$6.53B	$7.24B
Total Liabilities	$9.28B	$9.57B	$9.55B	$9.76B	$10.34B
Retained Earnings	$8.46B	$8.50B	$8.70B	$8.64B	$8.78B
Shareholders' Equity	$8.31B	$8.47B	$8.70B	$8.62B	$8.73B
Working Capital	$1.73B	$1.37B	$1.45B	$1.20B	$1.92B
Net Debt	$5.20B	$4.93B	$4.98B	$5.05B	$5.35B

LH Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	$18.50M	$620.60M	$387.20M	$614.20M	$191.50M
Capital Expenditure	-$126.00M	-$77.90M	-$106.70M	-$123.90M	-$121.00M
Free Cash Flow	-$107.50M	$542.70M	$280.50M	$490.30M	$70.50M
Depreciation & Amortisation	$166.80M	$170.30M	$171.00M	$173.00M	$173.30M
Stock-Based Compensation	$32.80M	$34.10M	$29.20M	$29.70M	$31.70M
Investing Cash Flow	-$336.00M	-$94.10M	-$374.00M	-$389.90M	-$322.10M
Financing Cash Flow	-$839.70M	-$267.40M	-$59.50M	-$290.40M	$580.50M
Dividends Paid	-$61.60M	-$59.90M	-$59.90M	-$59.30M	-$61.20M
Share Repurchases	$0.00	-$200.00M	-$25.00M	-$225.00M	-$98.00M
Net Change in Cash	-$1.16B	$259.10M	-$46.30M	-$66.10M	$449.90M

Market Snapshot

About

Labcorp Holdings Inc. is one of the world's leading global life sciences companies, providing comprehensive clinical laboratory and end-to-end drug development services. The company operates through two segments: Diagnostics Laboratories, offering routine and specialty testing services to healthcare providers and patients, and Biopharma Laboratory Services, supporting pharmaceutical companies in drug development from early research through post-market monitoring. Labcorp serves millions of patients and healthcare providers across more than 100 countries with a network of laboratories and patient service centers.